Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997666 | 1.00 | KDM4E (0.58) | KDM4ESMN1; SMN2KMT2AALDH1A1NPC1 | |
| SCHEMBL13242546 | 0.91 | CA12 (0.58) | KDM4ESMN1; SMN2KMT2AALDH1A1NPC1 | |
| SCHEMBL13704175 | 0.91 | BACE1 (0.53) | KDM4ESMN1; SMN2KMT2AALDH1A1CA12 | |
| SCHEMBL4326745 | 0.91 | KDM4E (0.60) | KDM4ESMN1; SMN2KMT2AALDH1A1NPC1 | |
| SCHEMBL2998925 | 0.88 | KDM4E (0.55) | KDM4ESMN1; SMN2KMT2AALDH1A1NPC1 | |
| SCHEMBL2998919 | 0.88 | KDM4E (0.55) | KDM4ESMN1; SMN2KMT2AALDH1A1NPC1 | |
| SCHEMBL4328629 | 0.87 | MAPT (0.56) | KMT2ANPC1RAB9AATMGSK3B | |
| SCHEMBL4335303 | 0.87 | MAPT (0.56) | KMT2ANPC1RAB9AATMGSK3B | |
| SCHEMBL13704191 | 0.83 | KDM4E (0.68) | KDM4ESMN1; SMN2KMT2AALDH1A1NFE2L2 | |
| SCHEMBL2995205 | 0.83 | TTR (0.54) | KDM4ESMN1; SMN2KMT2AALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2010-07-15 | — | — | US | claimed |
| EP-2167070-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | Nicox S.A. (FR) | 2010-03-31 | — | — | EP | claimed |
| WO-2009007230-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2009-01-15 | — | — | WO | claimed |
| EP-1709155-B1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTPR LTD (KY) | 2013-10-02 | — | — | EP | disclosed |
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2010-07-15 | — | — | US | disclosed |
| EP-2167070-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | Nicox S.A. (FR) | 2010-03-31 | — | — | EP | disclosed |
| US-7585997-B2 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTERPRISES LIMITED (KY) | 2009-09-08 | — | — | US | disclosed |
| WO-2009007230-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2009-01-15 | — | — | WO | disclosed |
| EP-1709155-A4 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1709155-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | Kashfi, Khosrow (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC. (CA) | 2005-08-18 | — | — | US | disclosed |
| WO-2005065361-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NOS1, NOS2, NOS3 | KDM4E 3010/4885SMN1; SMN2 489/4885KMT2A 4349/4885 |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | PYGL, TP53, MKI67 | KDM4E 4082/4885SMN1; SMN2 2772/4885KMT2A 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.